Eiger's Lonafarnib Loses EU Fast-Track Review Status
Potential Progeria Treatment Has Reverted To Standard Review
Eiger attributes the change in status of the EU marketing authorization application for lonafarnib to the need for an inspection and the ongoing coronavirus pandemic.
